solid progress numer busi segment even sell
maintain buy rate pt
follow result saw report top-lin growth y/i xfx
hit high end zbh state wamgr beat
btig/consensu estim y/i initi upgrad share
ahead print view rosa result would abl power growth
upward state wamgr toward higher end rang come
top line result xfx acceler beyond y/i power
strength knee y/i xfx hip y/i xfx y/i xfx
spine cmf continu drag result improv sequenti
y/i xfx y/i xfx benefit extra sell day
estim even sequenti improv seen
variou categori furthermor management describ strength knee come
multipl driver less half come rosa remaind mix
organ strength gain cementless knee impli
sequenti improv underli knee growth guidanc remain
unchang year call xfx revenu
growth line adj gm expand bp y/i sg percentag
revenu declin y/i first time sinc expect see
margin headwind management focus top line clear driver expans
beyond evid calendar progress see
path toward acceler top line growth on-going salesforc product
initi multipl avenu margin expans ultim accret alloc
capit de-lever
rosa knee dynam zbh knee franchis grew y/i
management state less half growth came rosa assum
revenu gener rosa impli unit sold earli
util dynam appear impress management call close
procedur perform date system indic strong demand
even estim instal base high addit persona
revis system enter market expect improv
hip improv even without rosa would note hip grew
xfx account sell day impact growth
improv management note new product contribut growth
rosa yet gain clearanc hip applic materi
driver time
multipl margin driver management disclos expect margin headwind
would outweigh tailwind move beyond
multipl driver expans top line growth mix expect provid
boost gm off-set capit inventori cog line
sg effici improv capit alloc expect benefit
beyond
valuat rate buy pt base month
ep estim risk discuss
idc btig estim compani document
million except per share amount
made signific improv turnaround busi risk tabl believ
major manufactur cultur challeng exist prior diminsh expect improv
growth profil move progress higher result wamgr see
upsid expect base market interest rosa new product launch top-lin
improv subsequ expect adj ebitda margin improv modestli result better
full commerci launch rosa knee
launch rosa spine
lap qualiti remedi effort improv inventori level
base case scenario fall high end guidanc
estim revenu rise report basi compar guidanc call
 adjust ep come compar guidanc
call
upsid estim could come faster expect adopt
npi reinvigor sale forc follow suppli improv addit
upsid could seen rosa system gain rapid adopt allow
implant share gain purchas account
resurfac qualiti suppli issu worsen compani sale forc
moral shrink margin combat competitor disappoint launch
rosa could contribut wors expect result
zimmer biomet diversifi
medic technolog compani
design manufactur broad
rang orthopaed reconstruct
product zimmer hold
found justin
zimmer took current
form zimmer acquir
biomet inc april today
zimmer biomet oper global
countri
employe across world
zimmer biomet report result overal revenu came y/i y/i xfx beat btig
consensu expect y/i y/i segment report revenu
y/i knee y/i hip y/i y/i dental
y/i spine cmf y/i compar btig/consensu estim
y/i y/i constant currenc revenu growth
btig expect gross margin adjust in-lin btig estim inventori initi
cost continu declin sg percentag revenu came versu btig estim call
revenu versu btig estim told adjust ep quarter btig
consensu estim
made follow chang model
within zbh revenu mix left estim unchang within tweak
estim knee hip slightli account better perform within segment left estim
unchang dental lower estim slightli within spine cmf busi taken
longer improv previous assum overal revenu estim remain larg unchang
actualsbtig estimate variancetot net bpssg spend bpsr spend bpsadj ebit bpsadj ebitda bpstax bpssourc btig research estim compani filingsvari
 tweak oper expens account slightli lower ramp adj om
previous assum bp improv adj om model bp improv lower expect
gm base fx hedg revers management commentari length time expect realiz margin gain
manufactur inventori initi expect sg slightli higher previous assum
invest new product off-set somewhat lower interest tax expens overal ep estim come
slightli result higher oper expens
zimmer biomet rate buy pt base month ep estim larg cap med-tech
peer current trade ntm ep trade ntm ep believ multipl appropri
given histor valuat spread rel ihi typic trade ihi impli
risk rate pt includ loss market share competitor inabl remov risk relat manufactur
slower rosa commerci anticip lack consist execut goal lack margin expans
due increas invest
btig research estim compani filingsnewold chang
incom etot y/i sale special oper incom incom tax expens net share net incom share gross net net oper tax expens btig research estim compani report
revenu y/i btig research estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
